AbstractBackground: Breast cancer in the elderly is associated withhigh recurrence and death rates, due mostly to undertreatment.Human epidermal growth factor receptor type 2(HER2) overexpression is infrequent in older patients. Trastuzumab-based chemotherapy is often withheld from elderlypatients because of its cardiotoxicity. Patients and Methods:Medical records of consecutive HER2-positive breastcancer patients aged ≥ 70 years old treated between 2005and 2010 in the participating centers were retrospectivelyreviewed. All patients underwent multidimensional geriatricassessment (MGA). Results: Among 59 patients identified,51 patients were evaluable (median age 76 years). The rateof any adverse event was 20% (10/51). The most relevant cardiacadverse event consisted of symptomatic congestiveheart failure (CHF; n = 1, 2%) followed by asymptomatic decreasesof left ventricular ejection fraction (LVEF; n = 6, 12%).Other toxicities included moderate hypersensitivity reactions during trastuzumab infusions (n = 3, 6%). Hypertension,obesity, prior anthracyclines exposure and concurrentchemotherapy were associated with a higher incidence oftoxic events. Previous radiotherapy, concurrent endocrinetherapy and different trastuzumab-based regimens did notseem to influence toxicity. Conclusions: Our data suggestthat trastuzumab has a good safety profile in nonfrail womenaged 70 years and older. These favorable findings may berelated to a limited number of anthracycline pretreatments,patient selection and a close cardiologic monitoring.
|Numero di pagine||6|
|Stato di pubblicazione||Published - 2013|
All Science Journal Classification (ASJC) codes